These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7663216)

  • 1. Service provision and use of anticoagulants in atrial fibrillation.
    Sudlow CM; Rodgers H; Kenny RA; Thomson RG
    BMJ; 1995 Aug; 311(7004):558-60. PubMed ID: 7663216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should we just let the anticoagulation service do it? The conundrum of anticoagulation for atrial fibrillation.
    Matchar DB; Samsa GP; Cohen SJ
    J Gen Intern Med; 1996 Dec; 11(12):768-70. PubMed ID: 9016428
    [No Abstract]   [Full Text] [Related]  

  • 3. Recent national patterns of warfarin use in atrial fibrillation.
    Stafford RS; Singer DE
    Circulation; 1998 Apr; 97(13):1231-3. PubMed ID: 9570191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary stroke prevention in nonvalvular atrial fibrillation: implementing the clinical trial findings.
    Howard PA; Duncan PW
    Ann Pharmacother; 1997 Oct; 31(10):1187-96. PubMed ID: 9337445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential use of decision analysis to support shared decision making in the face of uncertainty: the example of atrial fibrillation and warfarin anticoagulation.
    Robinson A; Thomson RG;
    Qual Health Care; 2000 Dec; 9(4):238-44. PubMed ID: 11101709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic warfarin: a cost-effective alternative to brand-name drug or a clinical wild card?
    DeCara JM; Croze S; Falk RH
    Chest; 1998 Feb; 113(2):261-3. PubMed ID: 9498932
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation.
    Gage BF; Cardinalli AB; Albers GW; Owens DK
    JAMA; 1995 Dec; 274(23):1839-45. PubMed ID: 7500532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis.
    Quinn RR; Naimark DM; Oliver MJ; Bayoumi AM
    Am J Kidney Dis; 2007 Sep; 50(3):421-32. PubMed ID: 17720521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of service provision for anticoagulation in atrial fibrillation. Many patients are ineligible.
    Lip GY
    BMJ; 1996 Jan; 312(7022):51. PubMed ID: 8555867
    [No Abstract]   [Full Text] [Related]  

  • 11. Warfarin use in atrial fibrillation: A random sample survey of family physician beliefs and preferences.
    Pradhan AA; Levine MA
    Can J Clin Pharmacol; 2002; 9(4):199-202. PubMed ID: 12584578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives.
    Blann AD; Boriani G; Lip GY
    Europace; 2016 Oct; 18(10):1507-1513. PubMed ID: 27876695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation.
    Amin A; Stokes M; Wu N; Gatt E; Makenbaeva D; Wiederkehr D; Boulanger L
    J Med Econ; 2013 Oct; 16(10):1193-202. PubMed ID: 23883416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation for patients with atrial fibrillation and risk factors for stroke. Warfarin reduces the risk by two thirds, but doctors still aren't prescribing it enough.
    Connolly SJ
    BMJ; 2000 May; 320(7244):1219-20. PubMed ID: 10797015
    [No Abstract]   [Full Text] [Related]  

  • 17. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
    O'Brien CL; Gage BF
    JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physician practices regarding anticoagulation and cardioversion of atrial fibrillation.
    Schlicht JR; Davis RC; Naqi K; Cooper W; Rao BV
    Arch Intern Med; 1996 Feb; 156(3):290-4. PubMed ID: 8572839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Warfarin at Discharge Among Acute Ischemic Stroke Patients With Nonvalvular Atrial Fibrillation in China.
    Yang X; Li Z; Zhao X; Wang C; Liu L; Wang C; Pan Y; Li H; Wang D; Hart RG; Wang Y; Wang Y;
    Stroke; 2016 Feb; 47(2):464-70. PubMed ID: 26696643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis.
    Mendoza-Sanchez J; Silva F; Rangel L; Jaramillo L; Mendoza L; Garzon J; Quiroga A
    PLoS One; 2018; 13(5):e0196361. PubMed ID: 29723207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.